Regulatory Approval / Product Launch
Lupin Receives U.S. FDA Approval for Sodium Sulfate, Magnesium Sulfate and Potassium Chloride Tablets with 180-Day Exclusivity Opportunity
NSE
lupin
BSE
500257
Lupin Limited has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Sodium Sulfate, Magnesium Sulfate and Potassium Chloride Tablets, 1.479 g/0.225 g/0.188 g. Lupin is the exclusive first-to-file applicant for the product and is eligible for 180 days of generic drug exclusivity. The product references Sutab® Tablets and addresses a U.S. market with annual sales of approximately USD 132.8 million.
PRICE-SENSITIVE TRIGGER
Event: U.S. FDA Approval for Generic Drug Product
Type: Regulatory Approval / Product Launch
Impact: Positive
Immediate Effect: The approval enables Lupin to commercialize the generic version of Sutab® Tablets in the U.S. market and provides an opportunity to benefit from 180-day generic exclusivity as the exclusive first-to-file applicant.
Key Metrics:
- Product: Sodium Sulfate, Magnesium Sulfate and Potassium Chloride Tablets
- Dosage Strength: 1.479 g / 0.225 g / 0.188 g
- U.S. Market Size: USD 132.8 million (IQVIA MAT March 2026)
- Exclusivity Period: 180 days generic exclusivity
- Manufacturing Location: Nagpur, India
- Reference Drug: Sutab® Tablets
Highlight:
- Lupin has secured U.S. FDA approval as the exclusive first-to-file applicant, making it eligible for 180-day generic market exclusivity in a product category with annual U.S. sales of USD 132.8 million.
What Happened ?
Lupin Limited announced that it has received approval from the U.S. FDA for its ANDA for Sodium Sulfate, Magnesium Sulfate and Potassium Chloride Tablets, 1.479 g/0.225 g/0.188 g.
The approved product is bioequivalent to the reference listed drug Sutab® Tablets marketed by Azurity Pharmaceuticals, Inc.
Importantly, Lupin stated that it is the exclusive first-to-file applicant for this product and is therefore eligible for 180 days of generic drug exclusivity in the U.S. market.
The product is indicated for cleansing of the colon as a preparation for colonoscopy procedures in adults.
Manufacturing of the product will be undertaken at Lupin’s Nagpur manufacturing facility in India.
The approval expands Lupin’s U.S. generics portfolio and strengthens its position in the gastrointestinal therapeutics segment.
Key Details
U.S. FDA Approval Details:
- U.S. FDA approved Lupin’s ANDA for Sodium Sulfate, Magnesium Sulfate and Potassium Chloride Tablets.
- Approved strength is 1.479 g/0.225 g/0.188 g.
- Product is bioequivalent to Sutab® Tablets.
- Reference product is marketed by Azurity Pharmaceuticals.
- Lupin is the exclusive first-to-file applicant.
- Company is eligible for 180-day generic drug exclusivity.
- Product is indicated for colon cleansing before colonoscopy procedures.
- Manufacturing will be carried out at Lupin’s Nagpur facility.
- Addresses a U.S. market opportunity valued at approximately USD 132.8 million annually.
- Expands Lupin’s U.S. generic pharmaceutical portfolio.
Note:
- First-to-file status is strategically important because it can provide a temporary competitive advantage in the U.S. generics market, potentially supporting stronger product economics during the exclusivity period.
Risk Analysis
Summary:
- While the approval creates a commercial opportunity, actual revenue generation will depend on launch timing, market penetration, competitive dynamics after exclusivity expiry, and product uptake in the U.S. market.
Key Risks:
- Commercial success depends on execution of the U.S. product launch.
- Revenue realization is influenced by market share capture during exclusivity.
- Pricing pressure may increase after exclusivity period expires.
- Generic competition could intensify following market entry of additional players.
- Regulatory compliance and supply continuity remain important.
Worst Case Scenario:
- If product launch timing is delayed or market penetration remains below expectations during the exclusivity period, the commercial benefits from the approval may be lower than anticipated.
Risk Level: Low
Company Commentary
- Lupin received U.S. FDA approval for Sodium Sulfate, Magnesium Sulfate and Potassium Chloride Tablets.
- The product is bioequivalent to Sutab® Tablets.
- The company is the exclusive first-to-file applicant.
- Lupin is eligible for 180-day generic drug exclusivity.
- Manufacturing will be undertaken at the company’s Nagpur facility in India.
- The approved product is intended for colon cleansing prior to colonoscopy procedures.
Official Exchange Filing: Lupin Limited